Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: AMPH stock price vs PNW: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at PNW's multiple
Needs PNW P/E.
Implied fair value · at AMPH's multiple
Needs AMPH P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: AMPH FY 2025 (ended Dec 31, 2025) · PNW FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 61% equity / 39% debt · EV / Revenue 1.84x · EV / EBITDA 6.20x
Capital structure 55% equity / 45% debt · EV / Revenue 4.05x · EV / EBITDA 16.84x
PNW carries the larger enterprise value at $21.62B against $1.32B; AMPH trades on the lower EV / Revenue multiple (1.84x vs 4.05x); AMPH on the lower EV / EBITDA (6.20x vs 16.84x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Amphastar Pharmaceuticals, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
PINNACLE WEST CAPITAL CORP · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.79x
1.39x
Net debt / EBITDA
Leverage against operating earnings
1.58x
7.63x
Cash and equivalents
Liquid reserves on the balance sheet
$282.81M
$6.60M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
BRISTOL MYERS SQUIBB CO
AMPH vs BMY
TEVA PHARMACEUTICAL INDUSTRIES LTD
AMPH vs TEVA
Bausch Health Companies Inc.
AMPH vs BHC
PERRIGO Co plc
AMPH vs PRGO
ANI PHARMACEUTICALS INC
AMPH vs ANIP
AES CORP
AMPH vs AES
Duke Energy CORP
AMPH vs DUK
DOMINION ENERGY, INC
AMPH vs D
AMERICAN ELECTRIC POWER CO INC
AMPH vs AEP
EXELON CORP
AMPH vs EXC
SEMPRA
AMPH vs SRE
$619.71M
$9.81B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
